With de­layed re­view date loom­ing, Bris­tol My­ers un­corks more win­ning da­ta for block­buster-po­ten­tial heart drug

Bris­tol My­ers Squibb doled out a whop­ping $13 bil­lion for MyoKar­dia back in late 2020, main­ly on the block­buster hopes of heart drug mava­camten. De­spite some win­ning late-stage da­ta, the drug has seen noth­ing but de­lays — but an­oth­er big win could put some wind in Bris­tol My­ers’ sails as a key re­view date ap­proach­es.

On Wednes­day, Bris­tol My­ers re­vealed topline da­ta from the Phase III VAL­OR-HCM tri­al show­ing mava­camten best­ed place­bo in re­duc­ing the need for an in­va­sive pro­ce­dure in pa­tients with ob­struc­tive hy­per­trophic car­diomy­opa­thy (oHCM), the drug gi­ant said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.